|
Monopar Therapeutics Inc., a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar’s uPAR targeting antibody MNPR-101.
Highlights of the patent filing include:
Composition of Matter: Claims cover a family of linkers, as well as Monopar’s uPAR targeting agents linked with these along with therapeutic radioisotopes.
Stability and Biodistribution: These proprietary new linkers have been created to enhance the stability and biodistribution of Monopar’s array of therapeutic radiopharmaceuticals.
Versatility: The newly developed linker family works with a wide range of isotopes and targeting molecules, including small molecules/peptides and antibodies.
“This provisional patent could enable us to use these linkers to create new proprietary radiopharmaceuticals going after well-established, high-value cancer targets that we are interested in,” commented Andrew Cittadine, Monopar’s chief operating officer. “We also believe that these linkers may be of great interest to others in the industry, opening the door to potential licensing and development collaborations.”
“These novel linkers and compositions of matter exemplify Monopar’s passion and commitment to being an innovator in the radiopharma space,” said Chandler Robinson, MD, Monopar’s chief executive officer.
Monopar Therapeutics is a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, including phase 1-stage MNPR-101-Zr for imaging advanced cancers, phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac225 for the treatment of advanced cancers, as well as early development stage programmes against solid cancers.
|